India News | ICMR Says Clinical Trial Shows COVAXIN is 'safe'

New Delhi [India], January 3 (ANI): Hours after Drugs Controller General of India (DCGI) approved restricted use in an emergency situation to Bharat Biotech's COVID-19 vaccine, Indian Council of Medical Research (ICMR) on Sunday said data generated through pre-clinical studies and various phases of clinical trial shows COVAXIN is 'safe.'

"Data generated through pre-clinical studies and various phases of the clinical trial from within India highlighted COVAXIN's safety and immunogenicity. Potential of COVAXIN to mount a resistance against new mutants of SARS-CoV-2, the virus causing COVID-19, informed the decision making process for vaccine approval," ICMR tweeted.

Notably, COVAXIN is an indigenously developed coronavirus vaccine manufactured by Bharat Biotech in collaboration with the ICMR.

Earlier today, COVID-19 vaccines of Serum Institute of India and Bharat Biotech were granted permission for restricted use in an emergency situation by the Drugs Controller General of India (DCGI). (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)